SIMCERE PHARMAC. GRP LTD (S2P) - Total Liabilities
Based on the latest financial reports, SIMCERE PHARMAC. GRP LTD (S2P) has total liabilities worth €5.31 Billion EUR (≈ $6.21 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore S2P net assets growth trend to track the company's year-over-year net asset growth rate.
SIMCERE PHARMAC. GRP LTD - Total Liabilities Trend (2021–2025)
This chart illustrates how SIMCERE PHARMAC. GRP LTD's total liabilities have evolved over time, based on quarterly financial data. See SIMCERE PHARMAC. GRP LTD free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
SIMCERE PHARMAC. GRP LTD Competitors by Total Liabilities
The table below lists competitors of SIMCERE PHARMAC. GRP LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fonciere Lyonnaise
PA:FLY
|
France | €3.19 Billion |
|
Evolution Metals & Technologies Corp. Common Stock
NASDAQ:EMAT
|
USA | $12.63 Million |
|
The New India Assurance Company Limited
NSE:NIACL
|
India | Rs818.45 Billion |
|
Uxi Unicomp Technology Co. Ltd. A
SHG:688531
|
China | CN¥516.58 Million |
|
Varonis Systems
NASDAQ:VRNS
|
USA | $1.18 Billion |
|
DOF Group ASA
OL:DOFG
|
Norway | Nkr2.16 Billion |
|
Kinik Co
TW:1560
|
Taiwan | NT$5.38 Billion |
|
Luster LightTech Co. Ltd. Cl A
SHG:688400
|
China | CN¥2.05 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SIMCERE PHARMAC. GRP LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SIMCERE PHARMAC. GRP LTD market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SIMCERE PHARMAC. GRP LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SIMCERE PHARMAC. GRP LTD (2021–2025)
The table below shows the annual total liabilities of SIMCERE PHARMAC. GRP LTD from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.31 Billion ≈ $6.21 Billion |
+19.57% |
| 2024-12-31 | €4.44 Billion ≈ $5.19 Billion |
+22.33% |
| 2023-12-31 | €3.63 Billion ≈ $4.24 Billion |
-0.28% |
| 2022-12-31 | €3.64 Billion ≈ $4.26 Billion |
-1.55% |
| 2021-12-31 | €3.70 Billion ≈ $4.32 Billion |
-- |
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more